Therapy of metastatic bone pain

Journal of Nuclear Medicine

Volumn 42, Issue 6, 2001, Pages 895-906

  Serafini, A N ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Cancer; Metabolic radiotherapy; Pain; Radiopharmaceuticals; Treatment

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; HORMONE; NARCOTIC AGENT; PHOSPHORUS 32; PROCOLLAGEN C PROTEINASE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89; TIN;

BEAM THERAPY; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CANCER THERAPY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; NERVE BLOCK; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW;

ANALGESICS; ANIMALS; BONE NEOPLASMS; HUMANS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PHOSPHATES; PHOSPHORUS RADIOISOTOPES; RADIOISOTOPES; RADIOPHARMACEUTICALS; SAMARIUM; STRONTIUM; STRONTIUM RADIOISOTOPES;

EID: 0034977151     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. The management of intractable bone pain: A clinician's perspective
2. Bone metastases: Pathophysiology and management policy
3. Bone destruction in cancer
4. Pain in prostate cancer
5. The clinical course of bone metastases in breast cancer
6. Experience with patients suffering cancer pain in hospital
7. Bisphosphonates in breast carcinoma
8. Treatment of painful prostatic bone metastases with oral etidronate disodium
9. Salmon calcitonin treatment in bone metastases
10. Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer: Results of a controlled randomized study
11. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton
12. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
13. Bisphosphonates in prostate carcinoma
14. Overview of bisphosphonates
15. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bone metastases
16. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases
17. Local and systemic radiation for palliation of metastatic disease
18. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases
19. Half and total body irradiation for carcinoma of the prostate
20. Radiotherapy in the management of bone pain
21. Single dose half body irradiation for palliation of multiple bone metastases from solid tumors
22. The effect of single fraction compared to multiple fractions in painful bone metastases: A global analysis of the Dutch Bone Metastasis Study
23. Hemibody irradiation for metastatic bone pain in two histologically distinct groups of patients
24. A report of RTOG 8206: A phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases
25. Chemotherapy of bone metastases
26. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
27. Management options for painful carcinoma of the prostate
28. Palliative therapy with bone-seeking radiopharmaceuticals
29. Bone pain palliation
30. Cancer therapy using bone-seeking isotopes
31. Iodine-131 labeled diphosphonates for palliative treatment of bone metastases. ii. Preliminary clinical results with iodine-131 BDP3
32. Radionuclide diagnosis and therapy of neuroectodermal tumors using I-131 metaiodobenzylguanidine
33. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background
34. Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases
35. Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience
36. Phosphorous-32 for intractable bony pain from carcinoma of the prostate
37. Biological investigations with radioactive calcium and strontium: Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer
38. Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: Human biodistribution and dosimetric studies
39. Palliation of bone pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial
40. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease
41. Radionucleotide therapy of bone metastases: Prospects for enhancement of therapeutic efficacy
42. 89Sr for the treatment of incurable pain in patients with neoplastic osseous infiltrations
43. Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate
44. Strontium-89 radionuclide therapy: A dosimetric study using impulse response function analysis
45. Dose estimation strontium-89 radiotherapy of metastatic prostate cancer
46. Sr-89 radionuclide therapy: Dosimetry and hematological toxicity in two patients with metastasizing prostatic carcinoma
47. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma
48. Treatment of metastatic bone pain with strontium-89
49. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy
50. A prospective randomized double blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone
51. An evaluation of the safety and efficacy of treatment of Sr-89 in patients who previously received wide field radiotherapy
52. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: Preliminary report of a multicenter trial - UK Metastron Investigators Group
53. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
54. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
55. Efficacy of Sr-89 therapy in 200 patients with skeletal metastases from prostatic carcinoma
56. Selective accumulation of strontium-89 in metastatic bone deposits: Radiohistological correlation
57. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases
58. Effectiveness of the radioactive strontium-89 (Sr-89) chloride agent, SMS 2P, for pain palliation in patients with metastatic bone tumor in phase III multicenter clinical trial
59. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer
60. Efficacy and toxicity of intravenous strontium-89 for symptomatic osseous metastasis
61. Strontium-89 (Metastron) for palliative treatment of bony metastases: The University of Minnesota experience
62. Strontium chloride Sr-89 for treating pain from metastatic bone disease
63. Strontium-89 for treatment of painful bone metastases from prostate cancer
64. Strontium-89 therapy and imaging with bremsstrahlung in bone metastases
65. Strontium-89 in the treatment of bone metastases from breast cancer
66. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer
67. Comparison of P-32 and SHBI for bony metastases
68. The palliation of osseous metastases with P-32 or Sr-89 compared with external beam and hemibody irradiation: A historical perspective
69. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate
70. Modifying effect of steroid hormone therapy on human neoplastic disease as judged by radioactive phosphorous (P-32)
71. The treatment of painful osseous metastases with phosphorus-32 labeled phosphates
72. Consideration for the use of testosterone with systemic chemotherapy in prostatic cancer
73. Androgens and erythropoiesis
74. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases
75. The treatment of bone metastases with parathormone followed by radiophosphorus
76. Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents
77. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer
78. Dosimetry and toxicity by samarium-153-EDTMP administered for bone pain due to skeletal metastases
79. Radiation absorbed dose calculations for samarium-153-EDTMP localized in bone
80. Samarium-153-EDTMP biodistribution and dosimetry estimation
81. Evaluation of Sm-153-EDTMP as a bone imaging agent during a therapeutic trial
82. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial
83. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate
84. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP
85. 153Sm-EDTMP in a recurrent canine osteosarcoma
86. Pronounced therapeutic effect of samarium-153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma ibial tumor model
87. Samarium Sm-I53 lexidronam for the palliation of bone pain associated with metastasis
88. A double blinded placebo controlled study of Sm-153-EDTMP for the palliation of bone pain in patients with hormone refractory prostate carcinoma
89. A dose-controlled study of Sm-153-EDTMP in the treatment of patients with painful bone metastases
90. Multicenter trial on the efficacy and toxicity of single dose samarium-153 ethylenediamine methylene phosphonate as a palliative treatment for painful skeletal metastases in China
91. Efficacy and toxicity of 153-Sm-EDTMP in the palliative treatment of painful skeleton metastases: Results of an IAEA international multicenter study
92. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain
93. Multiple administration of Sm-153-lexidronam in the treatment of painful bone metastases
94. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormone resistant prostate cancer
95. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: Results of a double blind crossover comparison with placebo
96. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases
97. Re-186-HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer: Preliminary results
98. 186Re-etidronate in breast cancer patients with metastatic bone pain
99. Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: A phase I/II clinical study
100. New formulations of tin-117 stannic chelate therapy of cancer in bone
101. Strontium-89 and low dose infusion ablation for patients with hormone refractory prostate cancer metastatic to bone
102. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy
103. Radiosensitizatoin with low dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89
104. Strontium-89 combined with doxorubicin in the treatment of patients with androgen independent prostate cancer
105. Strontium-89 estramustine and vinblastine (SEV) in hormone refractory prostate cancer (HRPC): Concurrent chemoradiotherapy labs
106. Strontium-89 (Sr-89 Metastrone) and estramustine (EM) in hormone refractory prostate cancer (HRCP): A phase II study
107. Samarium-153-EDTMP and radiosensitizing chemotherapy for treatment of disseminated skeletal metastasis
108. Quantitation of biochemical markers of bone resorption following strontium-89 chloride therapy for metastatic prostate carcinoma
109. 89Sr and external beam radiotherapy of prostatic bony metastasis
110. A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic in bone
111. Painful bone metastasis in hormone refractory prostate cancer: Economic costs of strontium-89 and/or external radiotherapy
112. Palliative radiotherapy for skeletal metastasis: Cost substitution analysis and economic impact
113. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP
114. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate
115. In-vivo tissue uptake and retention of Sn-117m (4+) DTPA in a human subject with metastatic bone pain and in normal mice
116. Prospective 153-Sm-EDTMP therapy dosimetry by whole body scintigraphy
117. Tc-99m-MDP as a surrogate quantitative imaging agent for high dose Ho-166-DOTMP
118. 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy
119. A new method to quantify total bone uptake of Re-186 HEDP and Sm-153 EDTMP
120. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: Total outcome following strontium-89 therapy
121. Successful use of samarium-153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer